期刊文献+

脓肿分枝杆菌菌种鉴定及药物敏感试验研究 被引量:11

The analysis of species identification and susceptibility testing of Mycobacterium abscessus
原文传递
导出
摘要 目的 对于将脓肿分枝杆菌分为2个亚种的菌种鉴定方法进行分析评价,并分别进行药物敏感试验,了解不同的抗生素对各亚种的抑菌活性.方法 通过16S rRNA鉴定的60株脓肿分枝杆菌临床分离株,再应用rpoB和hsp65基因序列将其分为Abscessus和Massiliense亚种.2个亚种的耐药率比较采用x2或Fisher精确概率法检验,对抗生素耐药与erm(41)基因28位点的碱基进行相关性分析.结果 脓肿分枝杆菌中Abscessus亚种占65% (39/60),Massiliense亚种占35% (21/60).阿米卡星敏感菌株中Abscessus亚种占97% (38/39),Massiliense亚种占95% (20/21);阿奇霉素敏感菌株中Abscessus亚种占92% (36/39),Massiliense亚种占95% (20/21);亚胺培南敏感菌株中Abscessus亚种占74% (29/39),Massiliense亚种占67%(14/21).46% (18/39)的Abscessus亚种和76%(16/21)的Massiliense亚种对头孢西丁中度敏感,82% (32/39)的Abscessus亚种对克拉霉素耐药,95% (20/21)的Massiliense亚种对克拉霉素敏感.28株erm(41)基因测序成功的Abscessus亚种中,克拉霉素耐药菌株23株,其中22株erm(41)基因的28位点为T,1株为C;克拉霉素敏感菌株5株erm(41)基因的28位点均为C.结论 采用rpoB和hsp65基因序列可将脓肿分枝杆菌分为Abscessus和Massiliense亚种.阿奇霉素、阿米卡星和亚胺培南在体外对脓肿分枝杆菌抑菌活性较强,头孢西丁的抑菌活性较好,克拉霉素对Abscessus亚种的抑菌活性较差,而对Massiliense亚种的抑菌活性较好.erm(41)基因与克拉霉素耐药有相关性. Objectives To evaluate the method of differentiating Mycobacterium abscessus subsp.abscessus (subsp.M.abscessus) from Mycobacterium abscessus subsp.massiliense (subsp.M.massiliense),and to investigate the activity of different antibiotics in vitro.Methods Sixty Mycobacterium abscessus (M.abscessus) isolates previously identified by using 16S rRNA sequence,were identified by comparativesequence analysis of rpoB and hsp65,and were divided into subsp.M.abscessus and subsp.M.massiliense.Two subspecies' resistant proportions were compared by chi-square test.Finally the relationship between clarithromycin resistance and erm(41) was analyzed.Results Of all the 60 M.abscessus isolates,65% (39/60) belonged to subsp.M.abscessus,35% (21/60) belonged to subsp.M.massiliense.97% (38/ 39) subsp.M.abscessus and 95% (20/21) subsp.M.massiliense were susceptible to amikacin.92% (36/39) subsp.M.abscessus and 95% (20/21) subsp.M.massiliense were susceptible to azithromycin.74% (29/39) subsp.M.abscessus and 67 % (14/21) subsp.M.massiliense were susceptible to imipenem.46 % (18/39) subsp.M.abscessus and 76% (16/21) subsp.M.massiliense were moderately susceptible to cefoxitin.82% (32/39) subsp.M.abscessus were resistant to clarithromycin,and 95% (20/21) subsp.M.massiliense were susceptible to clarithromycin.Of all the 28 subsp.M.abscessus isolates which were sequenced suscessfully,23 isolates were resistant to clarithromycin,and 22 isolates in them had T28 in erm (41),and the rest one had C28 in erm(41).However,all the 5 subsp.M.abscessus isolates which were susceptible to clarithromycin had C28 in erm(41).Conclusions M.abscessus can be divided into subsp.M.abscessus and subsp.M.massiliense by using rpoB and hsp65.Amikacin,azithromycin and imipenem showed excellent inhibition activity against M.abscessus in vitro.Cefoxitin also showed a good inhibition activity.Clarithromycin had a poor inhibition activity against subsp.M.abscessus,but a good inhibition activity against subsp.M.massiliense.Erm(41) was related to clarithromycin resistance.
出处 《中华结核和呼吸杂志》 CAS CSCD 北大核心 2014年第7期517-521,共5页 Chinese Journal of Tuberculosis and Respiratory Diseases
基金 首都医学发展科研专项基金(2011-2016-02)
关键词 分枝杆菌属 微生物敏感性试验 抗药性 微生物 Mycobacterium Microbial sensitivity tests Drug resistance, microbial
  • 相关文献

参考文献13

  • 1Brown-Elliott BA,Wallace RJ Jr.Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria[J].Clin Microbiol Rev,2002,15:716-746.
  • 2Adékambi T,Berger P,Raoult D,et al.rpoB gene sequencebased characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp.nov.,Mycobacterium phocaicum sp.nov.and Mycobacterium aubagnense sp.nov[J].Int J Syst Evol Microbiol,2006,56(Pt1):133-143.
  • 3Adékambi T,Reynaud-Gaubert M,Greub G,et al.Amoebal coculture of " Mycobacterium massiliense " sp.nov.from the sputum of a patient with hemoptoic pneumonia[J].J Clin Microbiol,2004,42:5493-5501.
  • 4Leao SC,Tortoli E,Euzéby JP,et al.Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp.bolletii comb.nov.,designation of Mycobacterium abscessus subsp.abscessus subsp.nov.and emended description of Mycobacterium abscessus[J].Int J Syst Evol Microbiol,2011,61(Pt9):2311-2313.
  • 5Koh WJ,Jeon K,Lee NY,et al.Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus[J].Am J Respir Crit Care Med,2011,183:405-410.
  • 6Harada T,Akiyama Y,Kurashima A,et al.Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases[J].J Clin Microbiol,2012,50:3556-3561.
  • 7Nash KA,Brown-Elliott BA,Wallace RJ Jr.A novel gene,erm(41),confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae[J].Antimicrob Agents Chemother,2009,53:1367-1376.
  • 8Woods GL,Brown-Elliott BA,Conville PS,et al.Susceptibility testing of mycobacteria,nocardiae and other aerobic actinomycetes[M].Pennsylvania:Clinical and Laboratory Standards Institute,2012:41-42.
  • 9黄海荣,于霞,姜广路,戴广明,毕志强,马玙.利奈唑胺对分枝杆菌体外抑菌作用的初步研究[J].中华结核和呼吸杂志,2011,34(8):575-578. 被引量:28
  • 10Schr(o)der KH,Naumann L,Kroppenstedt RM,et al.Mycobacterium hassiacum sp.nov.,a new rapidly growing thermophilic mycobacterium[J].Int J Syst Bacteriol,1997,47:86-91.

二级参考文献14

  • 1Young LS. Reconsidering some approved antimicrobial agents for tuberculosis. Antimicrob Agents Chemother, 2009. 53: 4577- 4579.
  • 2Nannini EC, Keating M, Binstock P, et al. Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezotid and mefloquine. J Infect, 2002, 44 : 201-203.
  • 3Fortun J, Martin-Davila P, Navas E, et al. Linezolid for the treatment of muhidrug-resistant tubereulosis. J Antimierob Chemother, 2005, 56: 180-185.
  • 4Schecter GF, Scott C, True L, et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis, 2010, 50: 49- 55.
  • 5Anger HA, Dworkin F, Sharma S, et al. Linezolid use for treatment of muhidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J Antimicrob Chemother, 2010, 65: 775-783.
  • 6Koh WJ, Kwon O J, Gwak H, et al. Daily 300 mg dose of linezolid for the treatment of intractable muhidrug-resistant and extensively drug-resistant tuberculosis. J Antimierob Chemother, 2009, 64: 388-391.
  • 7Franzblau SG, Witzig RS, McLaughlin JC, et al. Rapid, low- technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J Clin Microbiol, 1998, 36: 362-366.
  • 8Lewis RE, Diekema DJ, Messer SA, et al. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother, 2002, 49: 345-351.
  • 9Huang TS, Liu YC, Sy CL, et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years. Antimicrob Agents Chemother, 2008, 52: 2226-2227.
  • 10Rodriguez JC, Ruiz M, Lopez M, et al. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents, 2002, 20: 464-467.

共引文献27

同被引文献89

引证文献11

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部